On January 3, 2022 MaaT Pharma (EURONEXT: MAAT – the "Company"), a French clinical-stage biotech and a pioneer in the development of microbiome-based ecosystem therapies dedicated to improving survival outcomes for patients with cancer, reported that its CEO and co-founder, Hervé Affagard will present the company at the upcoming H.C. Wainwright Bioconnect Virtual Conference held January 10-13, 2022 (Press release, MaaT Pharma, JAN 3, 2022, View Source [SID1234597959]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 am EST/1:00 pm CET on Monday, January 10, 2022.

A replay of the presentation will also be made accessible in the investors’ section of the company’s website at www.maatpharma.com from Friday, January 14, 2022 and for 90 days after the event.